No retraction, correction or concern found when last checked on Oct 24, 2026.

Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions

Nicola Riccardo Pugliese, Pierpaolo Pellicori, Francesco Filidei and 6 more

Cardiovascular Research · 2022 · Review · CC BY

Abstract

Many patients with symptoms and signs of heart failure have a left ventricular ejection fraction ≥50%, termed heart failure with preserved ejection fraction (HFpEF). HFpEF is a heterogeneous syndrome mainly affecting older people who have many other cardiac and non-cardiac conditions that often cast doubt on the origin of symptoms, such as breathlessness, or signs, such as peripheral oedema, rendering them neither sensitive nor specific to the diagnosis of HFpEF. Currently, management of HFpEF is mainly directed at controlling symptoms and treating comorbid conditions such as hypertension, atrial fibrillation, anaemia, and coronary artery disease. HFpEF is also characterized by a persistent increase in inflammatory biomarkers. Inflammation may be a key driver of the development and progression of HFpEF and many of its associated comorbidities. Detailed characterization of specific inflammatory pathways may provide insights into the pathophysiology of HFpEF and guide its future management. There is growing interest in novel therapies specifically designed to target deregulated inflammation in many therapeutic areas, including cardiovascular disease. However, large-scale clinical trials investigating the effectiveness of anti-inflammatory treatments in HFpEF are still lacking. In this manuscript, we review the role of inflammation in HFpEF and the possible implications for future trials.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 24, 2026. Paragraph numbers are ours, so an answer can point at one.

1This manuscript was handled by Guest Editor Carolyn S.P. Lam.

2This article is part of the Spotlight Issue on Heart Failure.

Introduction

3Many patients diagnosed with heart failure (HF) have a left ventricular ejection fraction (LVEF) ≥50%, i.e. HF with preserved LVEF (HFpEF). Nevertheless, making a diagnosis of HFpEF is challenging. Most patients are elderly, with a high proportion of women and several cardiovascular and non-cardiovascular comorbidities. Outpatients with HFpEF have a better overall prognosis and a much lower rate of cardiovascular events than those with HF with reduced LVEF (HFrEF), but a higher proportion of non-cardiovascular deaths. However, among patients with decompensated HF, the outcome is similar for HFpEF and HFrEF, although the prognosis for HFpEF might often be driven by comorbid disease rather than HF itself. Also, HFpEF and HFrEF are not entirely distinct entities. Indeed, impaired myocardial contraction is expected in both, e.g. circumferential for HFrEF and long axis for HFpEF., However, measurement of LVEF is prone to substantial error—hence the introduction of the HFmrEF phenotype, which acts as a buffer zone to reduce classification error between HFrEF and HFpEF in research and clinical practice. HFrEF may recover, especially for younger patients with little myocardial scar (e.g. dilated cardiomyopathy) who receive guideline-recommended therapy; this should not be considered HFpEF but rather HF with recovered LVEF., For patients with HFpEF, LVEF may also drop over time due to measurement error [increased with the onset of atrial fibrillation (AF)] or additional myocardial insults (e.g. myocardial infarction).

4A series of randomized control trials (RCTs) of neurohormonal antagonists failed to show clear cardiovascular benefits in patients with HFpEF. Recently, a RCT on a factor Xa antagonist demonstrated a substantial reduction in mortality for patients with HFpEF and coronary artery disease (CAD), while two others found that sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce hospitalizations for worsening HF., These trials showing that the natural history of HFpEF can be favourably modified encourage exploring other therapeutic avenues, including inflammation, which might have a key role in the pathophysiology underlying HFpEF. A thorough characterization of inflammatory pathways involved in HFpEF might help identify therapeutic targets and interventions. Herein, we provide an overview of the role of inflammation in the pathogenesis of HFpEF, summarize the available evidence for anti-inflammatory treatments, and discuss the potential implications for the design of future HFpEF trials. We deliberately avoid a detailed discussion of antifibrotic therapies because fibrosis is a non-specific downstream consequence of myocardial damage.,

The inflammatory-metabolic phenotype and HFpEF

5Inflammatory biomarkers, including tumour necrosis factor (TNF)-α and its receptors (TNFR1 and TNFR2), interleukin (IL)-6 and IL-8, high-sensitivity C-reactive protein (hsCRP), pentraxin-3 and the chemokine (C–C motif) ligand 2 (CCL2), also referred to as monocyte chemoattractant protein-1 (MCP-1), are often elevated in patients with HFpEF., Chronic, low-grade, systemic inflammation might have detrimental effects on myocardial structure and function (Graphical Abstract). Experimental models suggest that increased production of pro-inflammatory cytokines enhances oxidative stress, drives the differentiation of fibroblasts into collagen-secreting myofibroblasts, and induces extracellular matrix degradation, leading to increased myocardial stiffness and coronary microvascular dysfunction (CMD)., Local inflammation also reduces nitric oxide (NO) and cyclic guanosine monophosphate (cGMP) availability, resulting in the hypo-phosphorylation of the giant sarcomeric protein titin, which further increases myocardial stiffness and worsens diastolic function. Oxidative stress might also be implicated in the development of metabolic heart disease, indicating bidirectional links between inflammation and cardiac dysfunction.

6Whether the persistent inflammation that characterizes HFpEF represents a causal factor or an epiphenomenon due to one or more pro-inflammatory comorbid conditions is not well understood. Indeed, inflammation is frequently associated with unhealthy ageing and several cardio-metabolic comorbidities (Graphical Abstract), e.g. obesity and altered adiposity, chronic kidney disease (CKD), hypertension, CAD, Type 2 diabetes mellitus (T2DM), AF, elevated serum uric acid (SUA) concentrations, and chronic obstructive pulmonary disease (COPD). Chronic low-grade inflammation might also contribute to the development of sarcopaenia and frailty, which are very common among outpatients with HFpEF, with a prevalence varying from 30 to 52%. All these features, particularly when combined, might lead to a poorer quality of life and drive cardiovascular and non-cardiovascular outcomes., Recently, proteomic bioprofiles have been investigated to identify potential mechanistic pathways associated with HF development. Systemic inflammation might mediate the association between several comorbidities and cardiac dysfunction, promoting the progression of disease.

7AF and HFpEF frequently co-exist. Chronically elevated left atrial pressures might produce adverse structural atrial remodelling and dysfunction that increase the risk of developing AF. On the other hand, AF, especially with a rapid ventricular response, leads to a decreased LV filling time and the loss of atrial contribution to LV filling; therefore, it might precipitate the onset or worsening of HFpEF. Biomarkers reflecting systemic congestion, inflammation, and fibrosis predict clinically overt AF as well as HFpEF and are associated with abnormal diastolic filling and reduced exercise capacity. Endothelial inflammation can cause CMD and myocardial fibrosis, which can induce both atrial and ventricular myopathy. In addition, systemic inflammatory and metabolic disorders have been linked to an expansion and pro-inflammatory transformation of epicardial adipose tissue (EAT) EAT accumulation may also impair atrial distension and contraction by its proximity to the myocardium, leading to mechanical dysfunction, electroanatomical fragmentation, and ultimately AF.,

8Patients with HFpEF may exhibit different inflammation patterns according to their comorbidities. Inflammation in hypertension is often driven by renin–angiotensin–aldosterone system activation., On the other hand, the inflammatory milieu of obese patients is primarily due to adipokines, i.e. cytokines secreted by both adipocytes and macrophages resident in adipose tissue. Patients with HFpEF who are obese have higher serum concentrations of many pro-inflammatory proteins (galectin-9, CD4, and TNF-related apoptosis-inducing ligand receptor 2). This heterogeneity in inflammatory phenotypes could lead to the application of precision medicine in HF treatment, with different therapeutic approaches according to the pattern of comorbidity.

9Other non-metabolic diseases cause a chronic, low-grade, systemic inflammatory response, and produce a clinical picture that fits the HFpEF definition. Amyloidosis is a systemic disorder characterized by the progressive deposition of fibrillary proteins that cause immune cell infiltration into tissues and pro-inflammatory cytokine production in various organs, eventually resulting in their failure. Amyloid deposition might be common in patients with HFpEF, but, until recently, the diagnosis of amyloidosis has seldom been considered and rarely investigated. Heart valve diseases, even if not severe, can worsen cardiac structure and function and contribute to HF symptoms in the presence of a normal LVEF: it is noteworthy that degenerative valve disease is the most frequent valvular disorder in Western countries and is characterized by calcification, which might, in turn, be related to inflammation. Chronic inflammatory disorders, such as inflammatory bowel disease and rheumatoid arthritis, have been linked to an increased risk of cardiovascular disease (CVD) and HF, especially during flares in disease activity., Periodontal disease is extremely common and associated with increased cardiovascular risk. The more severe the periodontitis, the higher the risk of developing HF; conversely, good oral hygiene reduces it.,

Inflammatory biomarkers

10The inflammatory profile of patients with HFpEF can be investigated by measuring plasma concentrations of inflammatory biomarkers. However, plasma concentrations reflect a steady-state between production and disposal and are not necessarily evidence of changes in inflammation. In the presence of renal or hepatic dysfunction, elevated plasma concentrations may reflect reduced clearance rather than increased production.

11The most explored inflammatory pathway involves the nucleotide oligomerization domain-like receptor family, pyrin domain-containing (NLRP3) inflammasome (Figure 1), with the subsequent cleavage and activation of IL-1β, IL-6, IL-12, IL-18 and, finally, the production of CRP in the liver. This pathway is driven by endogenous stimuli and defined as ‘sterile’ inflammation instead of exogenous-induced inflammation due to infection. In routine clinical practice, hsCRP is widely available, relatively stable in peripheral blood and the most commonly measured inflammatory biomarker. High concentrations of hsCRP are associated with more comorbidity and greater disease severity in HFpEF and HFrEF,, and predict a worse outcome, although for HFpEF this is mainly for non-cardiovascular events.

12In several population-based longitudinal registries including patients with cardiovascular risk factors, SUA levels are associated with an increased risk of all-cause and cardiovascular mortality at serum concentrations substantially lower than those used to define hyperuricaemia in clinical practice., One potential explanation for this association is the induction of systemic inflammation due to oxygen-free radical production during the conversion of purines to uric acid by xanthine oxidase., The ESC-EORP-HF-LT registry showed that higher SUA concentrations are associated with an adverse prognosis for both HFrEF and HFpEF. However, uric acid itself is a powerful antioxidant, which may account for why randomized trials of xanthine oxidase inhibitors have, so far, failed to show convincing cardiovascular benefits. A large randomized trial of allopurinol for patients with ischaemic heart disease (IHD) should report soon.

13Galectin-3 is a lectin expressed by activated cardiac macrophages and induces the secretion of IL-6. Elevated serum concentrations of galectin-3 are associated with adverse LV remodelling, cardiomyocyte hypertrophy, and myocardial fibrosis. In the Aldo-DHF trial, baseline serum concentrations of galectin-3 were inversely correlated with functional capacity and directly associated with NYHA class in HFpEF patients. Data from multiple RCTs and registries suggest that galectin-3 is an independent predictor of adverse outcomes in chronic and acutely decompensated HF, regardless of LVEF., Thus, galectin-3 has been proposed as a marker of fibrotic activity, potentially mediated by inflammation. However, it is excreted by the kidney, and not all studies have corrected for renal function.

14High serum concentrations of the soluble suppression of tumourigenicity 2 (sST2, the circulating form of the cellular ST2 receptor, expressed by cardiac and vascular cells together with its ligand IL-33 following cardiovascular injury) are also associated with increased myocardial fibrosis and inflammation as well as with poorer outcomes in patients HFpEF. Many other markers of inflammation, metabolic dysfunction, and extracellular matrix remodelling (e.g. tissue inhibitors of metalloproteinases, procollagen Type I C-terminal propeptide, and procollagen Type III N-terminal propeptide (PIIINP), adrenomedullin, cystatin C, and resistin) have prognostic significance in HFpEF but have yet to find a role in clinical practice.

15Ferritin binds to iron in cells. In the absence of other diseases, iron deficiency is associated with low release of ferritin, and low serum concentrations signify iron deficiency. However, in the presence of inflammation, serum ferritin leaks from cells rendering it unreliable as a marker of iron deficiency, which might mask a diagnosis of iron deficiency in HFpEF. Iron deficiency is common in HF, irrespective of LVEF and associated with adverse outcomes. Inflammation can also inhibit iron absorption and iron mobilization and/or utilization even when iron stores are not depleted. Pro-inflammatory cytokines (e.g. TNF-α, IL-1β, IL-6) upregulate the protein hepcidin, leading to reduced intestinal iron absorption and decreased iron mobilization from bone marrow stores. Intravenous iron administration in patients with systolic HF improves symptoms and clinical outcomes, but evidence of benefit is still lacking for those with HFpEF.

16Omics techniques such as single-cell RNA sequencing are an emerging tool for studying the transcriptional heterogeneity in both healthy and diseased hearts and the diversity of immune cells implicated in the development of CVD. Multi-omics approaches may soon uncover novel inflammatory cardiac pathways that offer new therapeutic opportunities.

Imaging techniques

17Echocardiography is the most widely available imaging technique and provides valuable information regarding structural and functional alterations in HFpEF. The E/e’ ratio is a widely used surrogate marker of LV filling pressures, but its clinical utility remains controversial, and it has not been used to select patients for any of the successful landmark trials of HFpEF. Left atrial volume and function might be the best marker to integrate left ventricular systolic and diastolic dysfunction, including the mitral apparatus and heart rhythm, but will be agnostic to the underlying pathophysiology. Echocardiography can also evaluate EAT accumulation, which is associated with greater inflammatory activity, impaired haemodynamics, worse symptoms, and a poorer prognosis in patients with HF.

18Echocardiography and, more generally, ultrasound represent a valuable tool to estimate congestion, which is central to the diagnosis and prognosis of HF and is also associated with increased inflammatory activity. In experimental conditions, the development of venous congestion activates the innate immune system and the secretion of pro-inflammatory cytokines in healthy individuals. Therefore, treatment targeted at congestion might improve inflammation. Intensification of therapy with loop diuretics had a mixed effect on biomarkers of immune activation and inflammation in one small study of HFrEF, but it normalized endotoxin, which is often increased in congestive HF due to altered gut permeability and subsequent translocation of lipopolysaccharide into the circulation.,

19Cardiac magnetic resonance (CMR) represents the gold standard for evaluating chamber geometry and structure, as well as quantifying EAT volume with great precision., CMR can also be used to estimate the extracellular volume and myocardial oedema. In HFpEF, the former correlates with myocardial stiffness and the extent of interstitial collagen deposition evaluated at the histopathological level, while the latter could be related to increased microvascular permeability or impaired lymphatic function.

20Localized myocardial inflammation can be assessed by positron emission tomography using [18F]fluorodeoxyglucose, which accumulates in activated inflammatory cells (monocyte, macrophage, lymphocyte) due to increased glucose uptake. Mechanistic studies suggest that [18F]fluorodeoxyglucose imaging after myocardial infarction (MI) and pressure-overload HF may provide additional prognostic information.

Inflammation as a therapeutic target in clinical trials of HFpEF

21Many large RCTs have investigated the effect of anti-inflammatory agents on cardiovascular events in patients with atherosclerosis, hypertension, and other cardiovascular disorders (Table 1). Most of these trials excluded patients with moderate or severe HF, did not always include HF-related endpoints and often did not provide data on LVEF,,,,, limiting extrapolation of their results to patients with HFpEF. Nevertheless, IHD is frequently undiagnosed and sub-optimally treated in patients with HFpEF. Not many patients with HFpEF undergo coronary angiography due to their advanced age, the high number of comorbidities, particularly renal dysfunction, and the lack of evidence that revascularization is beneficial in the absence of acute ischaemia. Of those who are investigated, many (>50%) have obstructive epicardial CAD, and most (85%) have evidence of CMD. The presence of CAD is not surprising, given the high proportion of patients with HFpEF who have hypertension, T2DM, obesity, and CKD. These comorbidities also account for the high prevalence of CMD, which may play a key pathophysiological role in the development of HFpEF, independent of atherosclerotic burden., Inflammation promotes all stages of atherosclerosis, from plaque formation to rupture, leading to macrovascular and microvascular ischaemic events., Also, chronic inflammation, even in the absence of epicardial stenoses and traditional coronary risk factors, is associated with CMD.

22Inflammation has been the therapeutic target for many RCTs that enrolled only patients with HF (Table 2 and Figure 2), but, until now, most of them were focused on the HFrEF phenotype.

Statins

23This drug class has several anti-inflammatory properties, including induction of endothelial NO synthase, inhibition of adhesion molecules expression, and reduction of immune cells chemotaxis. Administration of rosuvastatin is associated with a reduction in hsCRP. Nevertheless, in patients with HF, the effect of statins on disease progression and death remains uncertain. In the GISSI-HF trial, rosuvastatin showed no impact on time to death or admission to hospital for cardiovascular reasons in HF patients, irrespective of LVEF; however, only 10% of those enrolled had LVEF >40%. Interestingly, in the same trial, administration of n-3 polyunsaturated fatty acids reduced cardiovascular events by a small amount compared with placebo. In the CORONA trial, patients in the lowest tertile of aminoterminal-pro-brain natriuretic peptide (NT-proBNP) (roughly <1000 ng/L) had less severe disease and a better prognosis but appeared to benefit from a statin. Further analyses of the Heart Protection Study confirmed this finding, showing that as NT-proBNP and absolute cardiovascular risk increase, the relative risk reduction with statins shrinks, reaching a point where statin therapy is futile. A recent collaborative meta-analysis of unpublished data from major primary and secondary prevention RCTs showed that statins modestly reduced the risks of non-fatal HF hospitalization but not HF death. However, the authors did not have data on LVEF; relatively few were likely to have had HFpEF.

Nitric oxide signalling pathway

24NO is an intercellular messenger synthesized and released into the endothelial cells by NO synthases while converting arginine into citrulline. Impaired NO signalling is one of the cardinal features of endothelial dysfunction and atherosclerosis, as NO inhibits platelet aggregation and promotes vascular smooth muscle cell relaxation. NO regulates myocardial stiffness and diastolic function in healthy myocardium through the cGMP-protein kinase G pathway.,, Moreover, NO can also balance the functional activity, growth, and death of many immune and inflammatory cell types, including macrophages, T lymphocytes, antigen-presenting cells, mast cells, neutrophils, and natural killer cells. NO signalling could represent a therapeutic target for myocardial stiffness and inflammation, which are typical stigmata of HFpEF. In an inflammatory milieu, NO bioavailability is reduced by reactive oxygen species and the inactivation of endothelial NO synthase. However, in the RELAX trial, 216 patients with chronic HFpEF were randomized to a phosphodiesterase-5 inhibitor known to prolong NO half-life (sildenafil) or placebo. Sildenafil did not improve exercise performance. Likewise, in the NEAT-HFpEF and INDIE-HFpEF trials, nitrates/nitrites failed to improve daily activity level and exercise capacity in patients with HFpEF. Cimlanod, a nitroxyl donor, has been studied in patients with HFrEF in the STAND-UP AHF trial: compared with placebo, this drug led to decreased NT-proBNP plasma concentrations during infusion. In patients with chronic HFrEF, cimlanod showed haemodynamic effects similar to those of nitroglycerin, i.e. venodilatation and preload reduction without additional inotropic or lusitropic effects. Ongoing trials of cimlanod will further define its potential role in the treatment of HF.

25Vericiguat, an oral soluble guanylate cyclase stimulator, enhances the cGMP pathway by acting synergistically with NO. For patients with HFrEF, the VICTORIA trial suggested a reduction in morbidity and mortality, except in those with a very high NT-proBNP (>5314 ng/L) who appeared to be harmed. However, for patients with HFpEF (SOCRATES-PRESERVED, n = 477 and VITALITY-HFpEF, n = 789), vericiguat failed to reduce plasma NT-proBNP concentrations, left atrial volume, or physical activity.,

Colchicine

26Colchicine interferes with cytosolic microtubule assembly inhibiting immune cells chemotaxis and cytokines secretion, decreasing neutrophil L-selectin expression, thereby inhibiting diapedesis and inhibiting activation of the NLRP3 inflammasome, which is indirectly responsible for the cleavage of pro-IL-1β to active IL-1β. Colchicine has been extensively studied with encouraging findings in patients with IHD but with no apparent benefit for patients with chronic HFrEF. Two ongoing trials could provide valuable insights into the use of colchicine for HFpEF: the COLCOT-T2D will recruit 10 000 patients with T2DM but without known CAD and evaluate whether colchicine reduces cardiovascular risk and progression to HF; the COLpEF (NCT04857931) will enrol 426 patients with HFpEF to assess the effects of colchicine on hsCRP concentrations (primary outcome), symptoms, and other secondary outcomes.

Anti-IL-1

27More than 20 years ago, Ridker et al., described the significant association of serum concentrations of inflammatory biomarkers (e.g. IL-6 and CRP) with an increased risk of cardiovascular events. Recently, IL-6 has been associated with new-onset HFpEF in community-dwelling individuals. IL-1β is a key determinant of IL-6 production and has adverse effects on myocardial function in animal models, impairing systolic function, interfering with mitochondrial energy production and uncoupling β-adrenergic receptors, and L-type calcium channels.

28Canakinumab is a human monoclonal antibody targeting IL-1β, approved for treating many auto-immune diseases. In the CANTOS trial, 10 061 patients with a history of MI and hsCRP ≥2 mg/L were randomized to receive canakinumab in three different doses or placebo. After a median follow-up of 4 years, patients treated with the 150 mg and 300 mg dose had a lower incidence of the primary endpoint, a composite of non-fatal MI, non-fatal stroke, or cardiovascular death. In a prespecified analysis, the use of canakinumab led to a lower incidence of HF hospitalization and HF-related mortality; patients who achieved a hsCRP of <2 mg/L with treatment appeared to derive more benefit. However, there were no data on LVEF, precluding an analysis by LVEF phenotype.

29Anakinra is a recombinant antagonist of the IL-1 receptor, developed as a disease-modifying intervention for rheumatoid arthritis. The VCU-ART-3 trial enrolled 99 patients admitted for ST-elevation MI with a mean LVEF of 51%; anakinra reduced hsCRP compared with placebo. The D-HART enrolled 12 patients with HFpEF (median BNP 32 pg/mL) and hsCRP >2 mg/L were assigned to receive anakinra vs. matching placebo. After 14 days, patients assigned to anakinra had a lower hsCRP and greater peak VO2. However, the subsequent D-HART2, which included 32 obese patients with HFpEF and hsCRP >2 mg/L (median NT-proBNP 98 ng/L and 166 ng/L if assigned to placebo and anakinra, respectively), did not confirm an effect on VO2, but anakinra reduced hsCRP and NT-proBNP concentrations after 4 weeks.

Sodium-glucose cotransporter-2 inhibitors

30SGLT2i, or gliflozins, inhibit the kidney reabsorption of glucose but also appear to have anti-inflammatory effects. They were primarily developed to treat patients with T2DM, but recent landmark RCTs of HFrEF demonstrated that SGLT2i also reduce HF hospitalizations and cardiovascular death, whether or not the patients have T2DM.,, In the EMPEROR-Preserved trial, nearly 6000 patients with chronic HF and a LVEF >40% were randomized to empagliflozin or placebo. Empagliflozin reduced the incidence of the composite primary endpoint (hospitalization for HF or cardiovascular death), mostly due to a reduction in hospitalization. Haematocrit increased, NT-proBNP fell, and the decline in the estimated glomerular filtration rate was slowed. The benefit was observed for both HFmrEF (LVEF 40–49%) and HFpEF (LVEF ≥50%) regardless of a diagnosis of T2DM. The ongoing DELIVER trial will assess the effects of another SGLT2i, dapagliflozin, in HFpEF, probably establishing this class of drugs as a cornerstone for treating HFpEF.,

31SGLT2i cause a diuresis, resulting in a reduction in plasma volume and interstitial fluid, an increase in haematocrit and a reduction in body weight. Longer-term, SGLT2i might cause a further rise in haematocrit due to stimulation of erythropoietin and improved iron absorption and further loss in weight due to glycosuria and glucose wasting. However, diverse other potential mechanisms have been proposed, including an anti-inflammatory effect, reduction in oxidative stress and fibrosis, reduced deposition of advanced-glycation end-products, inhibition of the sodium/hydrogen exchanger-1 expressed on cardiomyocyte sarcolemma, and an increase in ketone body production as an energy substrate. Applying artificial intelligence to a cohort of patients with HFpEF, Bayes-Genis et al. recently proposed that SGLT2i act at a molecular level, reducing systemic inflammation by lowering the plasma concentration of NO synthase Type 2 and NLRP3 inflammasome. Improvement in cardiac function with administration of empagliflozin to nondiabetic patients with HFrEF has been linked to a reduction in serum markers of inflammation and EAT volume.,

Anticoagulants

32Activation of inflammatory pathways induces microvascular dysfunction and increases the risk of thrombotic events contributing to the progression of HF. The generation of thrombin can amplify the effects of other stimuli on inflammatory pathways, which might be ameliorated by reducing its production. The COMPASS trial randomized >27 000 patients with CAD in sinus rhythm to a combination of rivaroxaban 2.5 mg bd and aspirin compared with aspirin and rivaroxaban alone. The combination reduced cardiovascular events and mortality. The overall result was driven by a large benefit in a subgroup of 4250 patients with HFpEF and mild symptoms; patients with severe symptoms had been excluded. In contrast, the COMMANDER-HF, conducted in patients with HFrEF, CAD and in sinus rhythm who had a recent decompensation, showed no improvement in the primary endpoint (all-cause mortality, MI, or stroke) with low-dose rivaroxaban vs. placebo. Overall, these data suggest that the efficacy of this intervention, as for many others, depends on the patient profile. In patients with mild, stable HFpEF (and probably HFrEF), low-dose rivaroxaban may be rather effective, but in patients with more severe HF the dose is either too low or too late because other factors are driving progression.

Influenza and COVID vaccination

33Observational studies suggest that influenza vaccination may reduce mortality in patients with HF, and guidelines recommend considering this intervention in patients with HF.,, In a recent double-blind RCT including 2571 patients with a recent MI or severe CAD, influenza vaccination reduced the risk of all-cause mortality, MI or stent thrombosis after 12 months; benefits appeared very early, suggesting a therapeutic effect on the post-MI inflammatory phase. Unfortunately, the study was terminated prematurely due to the COVID-19 pandemic, but an observational study on >7000 patients with HF showed that COVID-19 vaccination was associated with a substantial reduction in all-cause hospitalization rates and mortality, irrespective of LVEF. RCTs are ongoing in patients with recent MI or HF.

Emerging anti-inflammatory targets with potential benefit in HFpEF

34HFpEF is associated with the activation of many inflammatory pathways; whether any of these are therapeutic targets is uncertain (Table 2).

Anti-IL-6

35Recent data suggest cross-talk between IL-1 and IL-6 signalling pathways in HF,, leading to increased hepatic CRP production. Elevated plasma IL-6 concentrations are a hallmark of persistent low-level ‘sterile’ inflammation related to unhealthy ageing, which is characterized by an augmented risk of metabolic and CVD (‘inflamm-ageing’)., Indeed, IL-6 can increase vascular smooth muscle cell stiffness and mitochondrial dysfunction, which explains the link between inflammation and impaired vascular function., Interestingly, Tet-2-mutated macrophages secrete higher amounts of IL-6, and these mutations are frequently seen in clonal haematopoiesis of indeterminate potential (CHIP), which is associated with an increased risk of cardiovascular events. In the BIOSTAT-HF study, more than half of the enrolled population had elevated serum concentrations of IL-6, associated with higher NT-proBNP and TNF-α, more iron deficiency, and poorer cardiovascular outcomes. Moreover, IL-6 administration in animal models was associated with myocardial hypertrophy and fibrosis, promoting diastolic dysfunction. Thus, IL-6 blockade might reduce the cardiovascular burden in HFpEF, but robust data are lacking. A subanalysis of the CANTOS trial showed the beneficial effects of canakinumab were more pronounced in those who achieved on-treatment IL-6 concentrations below the study median value of 1.65 ng/L. In patients with rheumatoid arthritis without CVD, inhibition of IL-6 receptor with tocilizumab was associated with improved LV systolic function and reduced LV mass. In the ASSAIL-MI trial, tocilizumab increased myocardial salvage as measured by CMR in patients with acute ST-segment elevation MI. Ziltivekimab, a fully human monoclonal antibody directed against the IL-6 ligand, reduced biomarkers of inflammation and thrombosis among patients with high cardiovascular risk, elevated hsCRP and CKD; a RCT is ongoing to evaluate its clinical value in patients with CV and renal disease (NCT05021835).

C–C chemokine receptor Type 2 modulation

36In mouse models, two subsets of cardiac macrophages can be identified according to the surface expression of C–C chemokine receptor 2 (CCR2). Tissue-resident CCR2– macrophages are the most represented subset in a normal heart, showing many cardioprotective properties, like promoting tissue regeneration and coronary angiogenesis. Conversely, only a small amount of inflammatory monocyte-derived CCR2+ macrophages is present in healthy mice. The latter initiate inflammation because they can induce neutrophil and monocyte migration into damaged tissues. Mice that developed chronic HF following coronary artery ligation had an increase in CCR2+/CCR2– ratio; findings subsequently confirmed in human hearts. CCR2 + macrophage abundance was associated with LV remodelling and more advanced systolic dysfunction in myocardial specimens obtained from HFrEF patients who underwent LV assist device implantation. An intense proliferation of CCR2+ macrophages has also been described in murine models of pressure overload obtained by aortic constriction. CCR2 modulation could represent a potential target to reduce inflammation and block the development of HFpEF: in murine models of angiotensin-II-induced HFpEF, inhibition of CCR2+ macrophages improved diastolic function, while in humans, the anti-CCR2 humanized monoclonal antibody MLN1202 (plozalizumab) reduced hsCRP in 112 individuals with CV risk factors. Ongoing exploratory trials targeting CCR2 in different diseases (e.g. T2DM and COPD) could hopefully pave the way to study this therapy in the whole HF spectrum.

Immunomodulation

37The systemic inflammatory state can be reduced by targeting cytokine pathways and a generalized modulation of the immune system activity. Cardiosphere-derived cells are a population of cardiac progenitor cells with prominent anti-inflammatory properties. In a rat model of hypertensive HFpEF, intracoronary treatment with cardiosphere-derived cells reduced serum concentrations of inflammatory cytokines, improved diastolic function, and decreased myocardial fibrosis, despite persistent hypertension. The ongoing REGRESS-HFpEF trial (NCT02941705) will assess whether intracoronary administration of cardiosphere-derived cells can reduce pro-inflammatory and pro-fibrotic signalling, as well as improve functional status and haemodynamics in patients with HFpEF.

Exercise training

38Impaired exercise capacity is a hallmark of HFpEF, which is likely to be multifactorial, including cardiac dysfunction, skeletal muscle deconditioning, obesity, co-existent lung or joint disease, and psychological factors. In patients with HFpEF, endurance exercise training was associated with increased functional capacity (as assessed by peak VO2) and quality of life but no improvement in endothelial function or arterial stiffness., Physical training reduces systemic vascular resistance and increases skeletal muscle perfusion, peripheral oxygen utilization, and mitochondrial function., These effects further modulate inflammatory and oxidative processes that may benefit patients with HFpEF.,

Epigenetics regulators

39The term ‘epigenetics’ encompasses the changes that affect gene activity and expression without involving alterations in the genome (DNA sequence). The administration of epigenetics regulators in animal models of hypertensive cardiomyopathy reduced TNF-α concentrations and interstitial myocardial fibrosis. The BETonMACE trial enrolled 2425 patients with T2DM up to 3 months after an acute coronary syndrome: participants were randomized to placebo and apabetalone, an inhibitor of bromodomain and extra-terminal motif proteins, which are epigenetic modulators of inflammation, thrombogenesis, and lipoprotein metabolism implicated in atherothrombosis. Although the trial missed its primary endpoint (MI, stroke, or cardiovascular death), in a prespecified secondary analysis, treatment with apabetalone was associated with a lower incidence of HF hospitalization than placebo {hospitalization for HF or cardiovascular death [5.7 vs. 7.8%, hazard ratio 0.72 (95% confidence interval 0.53–0.98), P = 0.04]}. Unfortunately, there were no data about LVEF; thus, further RCTs are needed to evaluate whether epigenetic modulators represent another promising therapeutic approach to preventing and treating HFpEF.

40Micro-RNA (miRNA) are small, non-coding RNAs involved in the RNA-induced silencing complex, which binds messenger RNA either inducing its degradation or inhibiting its translation at the ribosomal level. A single miRNA can act as an epigenetic modulator, regulating the expression of hundreds of different mRNAs without modifying the gene sequences. Several cardiovascular conditions seem to be associated with specific miRNAs: for example, serum concentrations of miR-210 and miR-1 correlate with symptom severity in HF., Furthermore, inhibition of miRNA-21 prevented the development of HFpEF in an experimental model.

Myeloperoxidase inhibitors

41Extracellular deposition of granulocyte-derived myeloperoxidase (MPO) can cause oxidative stress, leading to microvascular dysfunction, inflammation, tissue damage, and fibrosis. A novel MPO inhibitor (AZD4831) reduced inflammation and improved microvascular function in preclinical models. Target engagement and safety of AZD4831 have been tested in a Phase 2a study of HFpEF (NCT03756285), supporting further development.

Adrecizumab

42Adrenomedullin is a peptide hormone synthesized by endothelial and vascular smooth muscle cells. Its production is stimulated by volume overload to maintain endothelial barrier function, while the disruption of the adrenomedullin system results in vascular leakage and systemic and pulmonary oedema. Adrenomedullin is markedly elevated in patients with sepsis and in patients with acute HF, probably as a compensatory mechanism against fluid overload and tissue congestion. Adrecizumab is a monoclonal, non-neutralizing antibody that stabilizes adrenomedullin, ‘trapping’ it in the circulation without blocking adrenomedullin receptor signalling. In addition, adrecizumab translocates adrenomedullin from the tissue into the circulation. In animal models of systemic inflammation and septic shock, adrecizumab-induced increases in plasma adrenomedullin improved haemodynamics, renal function, and reduced markers of inflammation. A Phase II proof of concept study in patients hospitalized for acute HF is ongoing (NCT04252937).

Epicardial adipose tissue

43In patients with HFpEF, EAT accumulation is often marked, and it promotes haemodynamic derangements, altered adipogenesis by secretion of pro-inflammatory and pro-atherogenic adipokines, and an adverse prognosis. Noteworthy, increased biventricular hypertrophy and EAT exacerbate pericardial restraint in HFpEF, resulting in higher LV filling pressure to achieve a given transmural pressure, particularly during exercise. Enhanced pericardial restraint in patients with HFpEF partially explains the lower concentration of natriuretic peptides observed in this cohort, showing pathophysiology similar to that observed in constrictive pericarditis.

44Thus, in selected HFpEF patients, non-pharmaceutical interventions (e.g. exercise, diet, or bariatric surgery) or pharmacological therapies (e.g. SGLT2i and GLP-1 agonists) targeting excessive EAT accumulation might decrease inflammation and potentially provide meaningful clinical benefits.

Conclusions

45Subclinical inflammation is common in patients with HFpEF, regardless of underlying aetiology and associated comorbidities. A deeper understanding and detailed characterization of inflammatory mechanisms responsible for disease onset and progression may lead to new therapeutic opportunities to improve the well-being and outcomes of those with or at risk of developing HFpEF.

References 214

1.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J2021;42:3599–3726.
Not in our library10.1093/eurheartj/ehab368
2.
Anker MS, Hülsmann M, Cleland JG. What do patients with heart failure die from? A single assassin or a conspiracy?Eur J Heart Fail2020;22:26–28.
Not in our library10.1002/ejhf.1689
3.
Cleland JGF, McDonagh T, Rigby AS, Yassin A, Whittaker T, Dargie HJ. The national heart failure audit for England and Wales 2008–2009. Heart2011;97:876–886.
Not in our library10.1136/hrt.2010.209171
4.
Pellicori P, Kallvikbacka-Bennett A, Khaleva O, Carubelli V, Costanzo P, Castiello T, Wong K, Zhang J, Cleland JGF, Clark AL. Global longitudinal strain in patients with suspected heart failure and a normal ejection fraction: does it improve diagnosis and risk stratification?Int J Cardiovasc Imaging2014;30:69–79.
Not in our library10.1007/s10554-013-0310-y
5.
Cleland JGF, Pellicori P, Clark AL, Petrie MC. Time to take the failure out of heart failure: the importance of optimism. JACC: Heart Fail2017;5:538–540.
Not in our library10.1016/j.jchf.2017.04.003
6.
Halliday BP, Cleland JGF. Maintaining success for patients with dilated cardiomyopathy and remission of heart failure. JACC Basic Transl Sci2022;7:500–503.
Not in our library10.1016/j.jacbts.2022.03.008
7.
Clarke CL, Grunwald GK, Allen LA, Barón AE, Peterson PN, Brand DW, Magid DJ, Masoudi FA. Natural history of left ventricular ejection fraction in patients with heart failure. Circ Cardiovasc Qual Outcomes2013;6:680–686.
Not in our library10.1161/circoutcomes.111.000045
8.
Kotecha D, Piccini JP. Atrial fibrillation in heart failure: what should we do?Eur Heart J2015;36:3250–3257.
Not in our library10.1093/eurheartj/ehv513
9.
Branch KR, Probstfield JL, Eikelboom JW, Bosch J, Maggioni AP, Cheng RK, Bhatt DL, Avezum A, Fox KAA, Connolly SJ, Shestakovska O, Yusuf S. Rivaroxaban with or without aspirin in patients with heart failure and chronic coronary or peripheral artery disease the COMPASS trial. Circulation2019;140:529–537. Epub ahead of print 2019.
Not in our library10.1161/circulationaha.119.039609
10.
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner-La Rocca H-P, Choi D-J, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone S V, Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med2021;385:1451–1461.
Not in our library10.1056/nejmoa2107038
11.
Solomon SD, Vaduganathan M, Claggett BL, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Belohlavek J, Chiang CE, Willem Borleffs CJ, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O’Meara E, Kerr Saraiva JF, Tereschenko SN, Thierer J. Baseline characteristics of patients with HF with mildly reduced and preserved ejection fraction: DELIVER trial. JACC Hear Fail2022;10:184–197.
Not in our library10.1016/j.jchf.2021.11.006
12.
Adamo L, Rocha-Resende C, Prabhu SD, Mann DL. Reappraising the role of inflammation in heart failure. Nat Rev Cardiol2020;17:269–285.
Not in our library10.1038/s41569-019-0315-x
13.
Cleland JGF, Pellicori P, González A. A novel treatment for heart failure targets myocardial fibrosis. Nat Med2021;27:1343–1344.
Not in our library10.1038/s41591-021-01457-9
14.
Matsubara J, Sugiyama S, Nozaki T, Sugamura K, Konishi M, Ohba K, Matsuzawa Y, Akiyama E, Yamamoto E, Sakamoto K, Nagayoshi Y, Kaikita K, Sumida H, Kim-Mitsuyama S, Ogawa H. Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol2011;57:861–869.
Not in our library10.1016/j.jacc.2010.10.018
15.
Collier P, Watson CJ, Voon V, Phelan D, Jan A, Mak G, Martos R, Baugh JA, Ledwidge MT, McDonald KM. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?Eur J Heart Fail2011;13:1087–1095.
Not in our library10.1093/eurjhf/hfr079
16.
Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol2013;62:263–271.
Not in our library10.1016/j.jacc.2013.02.092
17.
Bairey Merz CN, Pepine CJ, Shimokawa H, Berry C. Treatment of coronary microvascular dysfunction. Cardiovasc Res2020;116:856–870.
Not in our library10.1093/cvr/cvaa006
18.
Xu L, Balzarolo M, Robinson EL, Lorenz V, Della Verde G, Joray L, Mochizuki M, Kaufmann BA, Valstar G, de Jager SCA, den Ruijter HM, Heymans S, Pfister O, Kuster GM. NOX1 mediates metabolic heart disease in mice and is upregulated in monocytes of humans with diastolic dysfunction. Cardiovasc Res2022;118:2973–2984.
Not in our library10.1093/cvr/cvab349
19.
Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol2020;17:559–573.
Not in our library10.1038/s41569-020-0363-2
20.
White Blood Cells and Blood Pressure · 2020
No notice
21.
Drummond GR, Vinh A, Guzik TJ, Sobey CG. Immune mechanisms of hypertension. Nat Rev Immunol2019;19:517–532.
Not in our library10.1038/s41577-019-0160-5
22.
Spiga R, Marini MA, Mancuso E, Di Fatta C, Fuoco A, Perticone F, Andreozzi F, Mannino GC, Sesti G. Uric acid is associated with inflammatory biomarkers and induces inflammation via activating the NF-κB signaling pathway in HepG2 cells. Arterioscler Thromb Vasc Biol2017;37:1241–1249.
Not in our library10.1161/atvbaha.117.309128
23.
Sze S, Pellicori P, Zhang J, Weston J, Clark AL. Identification of frailty in chronic heart failure. JACC Hear Fail2019;7:291–302.
Not in our library10.1016/j.jchf.2018.11.017
24.
Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O’Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA2013;309:1268–1277.
Not in our library10.1001/jama.2013.2024
25.
Sanders-Van Wijk S, Tromp J, Beussink-Nelson L, Hage C, Svedlund S, Saraste A, Swat SA, Sanchez C, Njoroge J, Tan RS, Fermer ML, Gan LM, Lund LH, Lam CSP, Shah SJ. Proteomic evaluation of the comorbidity-inflammation paradigm in heart failure with preserved ejection fraction: results from the PROMIS-HFpEF study. Circulation2020:2029–2044.
Not in our library10.1161/circulationaha.120.045810
26.
Ferreira JP, Verdonschot J, Wang P, Pizard A, Collier T, Ahmed FZ, Brunner-La-Rocca HP, Clark AL, Cosmi F, Cuthbert J, Díez J, Edelmann F, Girerd N, González A, Grojean S, Hazebroek M, Khan J, Latini R, Mamas MA, Mariottoni B, Mujaj B, Pellicori P, Petutschnigg J, Pieske B, Rossignol P, Rouet P, Staessen JA, Cleland JGF, Heymans S, Zannad F. Proteomic and mechanistic analysis of spironolactone in patients at risk for HF. JACC Hear Fail2021;9:268–277.
Not in our library10.1016/j.jchf.2020.11.010
27.
Santema BT, Arita VA, Sama IE, Kloosterman M, van den Berg MP, Nienhuis HLA, Van Gelder IC, van der Meer P, Zannad F, Metra M, Ter Maaten JM, Cleland JG, Ng LL, Anker SD, Lang CC, Samani NJ, Dickstein K, Filippatos G, van Veldhuisen DJ, Lam CSP, Rienstra M, Voors AA. Pathophysiological pathways in patients with heart failure and atrial fibrillation. Cardiovasc Res2022;118:2478–2487.
Not in our library10.1093/cvr/cvab331
28.
Packer M, Lam CSP, Lund LH, Redfield MM. Interdependence of atrial fibrillation and heart failure with a preserved ejection fraction reflects a common underlying atrial and ventricular myopathy. Circulation2020;141:4–6.
Not in our library10.1161/circulationaha.119.042996
29.
Pellicori P, Urbinati A, Kaur K, Zhang J, Shah P, Kazmi S, Capucci A, Cleland JGF, Clark AL. Prevalence and incidence of atrial fibrillation in ambulatory patients with heart failure. Am J Cardiol2019;124:1554–1560.
Not in our library10.1016/j.amjcard.2019.08.018
30.
Godo S, Takahashi J, Yasuda S, Shimokawa H. Role of inflammation in coronary epicardial and microvascular dysfunction. Eur Cardiol Rev2021;16:1625–1637.
Not in our library10.15420/ecr.2020.47
31.
Obokata M, Reddy YNV, Pislaru S V, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation2017;136:6–19.
Not in our library10.1161/circulationaha.116.026807
32.
Borlaug BA, Reddy YNV. The role of the pericardium in heart failure: implications for pathophysiology and treatment. JACC Hear Fail2019;7:574–585.
Not in our library10.1016/j.jchf.2019.03.021
33.
Koepp KE, Obokata M, Reddy YNV, Olson TP, Borlaug BA. Hemodynamic and functional impact of epicardial adipose tissue in heart failure with preserved ejection fraction. JACC Hear Fail2020;8:657–666.
Not in our library10.1016/j.jchf.2020.04.016
34.
Packer M. Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium. J Am Coll Cardiol2018;71:2360–2372.
Not in our library10.1016/j.jacc.2018.03.509
35.
Packer M. Drugs that ameliorate epicardial adipose tissue inflammation may have discordant effects in heart failure with a preserved ejection fraction as compared with a reduced ejection fraction. J Card Fail2019;25:986–1003.
Not in our library10.1016/j.cardfail.2019.09.002
36.
Hatem SN, Sanders P. Epicardial adipose tissue and atrial fibrillation. Cardiovasc Res2014;102:205–213.
Not in our library10.1093/cvr/cvu045
37.
Arakelyan M, Golukhova EZ, Gromova OI, Bulaeva NI. Epicardial adipose tissue and nonvalvular atrial fibrillation. Eur Heart J2021:42. Epub ahead of print 12 October 2021.
Not in our library
38.
Pugliese NR, Masi S, Taddei S. The renin–angiotensin–aldosterone system: a crossroad from arterial hypertension to heart failure. Heart Fail Rev2019:1–12.
Not in our library10.1007/s10741-019-09855-5
39.
Murray EC, Nosalski R, MacRitchie N, Tomaszewski M, Maffia P, Harrison DG, Guzik TJ. Therapeutic targeting of inflammation in hypertension: from novel mechanisms to translational perspective. Cardiovasc Res2021;117:2589–2609.
Not in our library10.1093/cvr/cvab330
40.
Wu H, Ballantyne CM. Metabolic inflammation and insulin resistance in obesity. Circ Res2020;126:1549–1564.
Not in our library10.1161/circresaha.119.315896
41.
Kresoja KP, Rommel KP, Wachter R, Henger S, Besler C, Klöting N, Schnelle M, Hoffmann A, Büttner P, Ceglarek U, Thiele H, Scholz M, Edelmann F, Blüher M, Lurz P. Proteomics to improve phenotyping in obese patients with heart failure with preserved ejection fraction. Eur J Heart Fail2021;23:1633–1644.
Not in our library10.1002/ejhf.2291
42.
Maffia P, Guzik TJ. When, where, and how to target vascular inflammation in the post-CANTOS era?Eur Heart J2019;40:2492–2494.
Not in our library10.1093/eurheartj/ehz133
43.
Siegismund CS, Escher F, Lassner D, Kühl U, Gross U, Fruhwald F, Wenzel P, Münzel T, Frey N, Linke RP, Schultheiss HP. Intramyocardial inflammation predicts adverse outcome in patients with cardiac AL amyloidosis. Eur J Heart Fail2018;20:751–757.
Not in our library10.1002/ejhf.1039
44.
Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, Roger VL, Gertz MA, Dispenzieri A, Zeldenrust SR, Redfield MM. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Hear Fail2014;2:113–122.
Not in our library10.1016/j.jchf.2013.11.004
45.
Goody PR, Hosen MR, Christmann D, Niepmann ST, Zietzer A, Adam M, Bönner F, Zimmer S, Nickenig G, Jansen F. Aortic valve stenosis: from basic mechanisms to novel therapeutic targets. Arterioscler Thromb Vasc Biol2020;40:885–900.
Not in our library10.1161/atvbaha.119.313067
46.
Kristensen SL, Ahlehoff O, Lindhardsen J, Erichsen R, Lamberts M, Khalid U, Nielsen OH, Torp-Pedersen C, Gislason GH, Hansen PR. Inflammatory bowel disease is associated with an increased risk of hospitalization for heart failure a Danish nationwide cohort study. Circ Hear Fail2014;7:717–722.
Not in our library10.1161/circheartfailure.114.001152
47.
Ahlers MJ, Lowery BD, Farber-Eger E, Wang TJ, Bradham W, Ormseth MJ, Chung CP, Stein CM, Gupta DK. Heart failure risk associated with rheumatoid arthritis-related chronic inflammation. J Am Heart Assoc2020;9: e014661. Epub ahead of print 18 May 2020.
Not in our library10.1161/jaha.119.014661
48.
Muñoz Aguilera E, Suvan J, Buti J, Czesnikiewicz-Guzik M, Barbosa Ribeiro A, Orlandi M, Guzik TJ, Hingorani AD, Nart J, D’Aiuto F. Periodontitis is associated with hypertension: a systematic review and meta-analysis. Cardiovasc Res2020;116:28–39.
Not in our library10.1093/cvr/cvz201
49.
Sharma S, Sridhar S, McIntosh A, Messow CM, Aguilera EM, Del Pinto R, Pietropaoli D, Gorska R, Siedlinski M, Maffia P, Tomaszewski M, Guzik TJ, D’Aiuto F, Czesnikiewicz-Guzik M. Periodontal therapy and treatment of hypertension-alternative to the pharmacological approach. A systematic review and meta-analysis. Pharmacol Res2021;166:105511.
Not in our library10.1016/j.phrs.2021.105511
50.
Causal association between periodontitis and hypertension: evidence from Mendelian randomization and a randomized controlled trial of non-surgical periodontal therapy · 2019
No notice
51.
Defilippi CR, Herzog CA. Interpreting cardiac biomarkers in the setting of chronic kidney disease. Clin Chem2017;63:59–65.
Not in our library10.1373/clinchem.2016.254748
52.
Murphy SP, Kakkar R, McCarthy CP, Januzzi JL. Inflammation in heart failure: JACC state-of-the-art review. J Am Coll Cardiol2020;75:1324–1340.
Not in our library10.1016/j.jacc.2020.01.014
53.
Pellicori P, Zhang J, Cuthbert J, Urbinati A, Shah P, Kazmi S, Clark AL, Cleland JGF. High-sensitivity C-reactive protein in chronic heart failure: patient characteristics, phenotypes, and mode of death. Cardiovasc Res2020;116:91–100.
Not in our library10.1093/cvr/cvz198
54.
Sanders-van Wijk S, van Empel V, Davarzani N, Maeder MT, Handschin R, Pfisterer ME, Brunner-La Rocca H-P. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction. Eur J Heart Fail2015;17:1006–1014.
Not in our library10.1002/ejhf.414
55.
Virdis A, Masi S, Casiglia E, Tikhonoff V, Cicero AFG, Ungar A, Rivasi G, Salvetti M, Barbagallo CM, Bombelli M, Dell'Oro R, Bruno B, Lippa L, D'Elia L, Verdecchia P, Mallamaci F, Cirillo M, Rattazzi M, Cirillo P, Gesualdo L, Mazza A, Giannattasio C, Maloberti A, Volpe M, Tocci G, Georgiopoulos G, Iaccarino G, Nazzaro P, Parati G, Palatini P. Identification of the uric acid thresholds predicting an increased total and cardiovascular mortality over 20 years. Hypertension2020;75:302–308.
Not in our library10.1161/hypertensionaha.119.13643
56.
Pugliese NR, Mengozzi A, Virdis A, Casiglia E, Tikhonoff V, Cicero AFG, Ungar A, Rivasi G, Salvetti M, Barbagallo CM, Bombelli M, Dell'Oro R, Bruno B, Lippa L, D'Elia L, Verdecchia P, Mallamaci F, Cirillo M, Rattazzi M, Cirillo P, Gesualdo L, Mazza A, Giannattasio C, Maloberti A, Volpe M, Tocci G, Georgiopoulos G, Iaccarino G, Nazzaro P, Parati G. The importance of including uric acid in the definition of metabolic syndrome when assessing the mortality risk. Clin Res Cardiol2021:1–10.
Not in our library10.1007/s00392-021-01815-0
57.
Carluccio E, Coiro S, Ambrosio G. Unraveling the relationship between serum uric acid levels and cardiovascular risk. Int J Cardiol2018;253:174–175.
Not in our library10.1016/j.ijcard.2017.11.035
58.
Ambrosio G, Leiro MGC, Lund LH, Coiro S, Cardona A, Filippatos G, Ferrari R, Piepoli MF, Coats AJS, Anker SD, Laroche C, Almenar-Bonet L, Poder P, Valero DB, Frisinghelli A, Maggioni AP. Serum uric acid and outcomes in patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes: analysis of the ESC-EORP heart failure long-term (HF LT) registry. Eur J Intern Med2021;89:65–75.
Not in our library10.1016/j.ejim.2021.04.001
59.
Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A1981;78:6858–6862.
Not in our library10.1073/pnas.78.11.6858
60.
Suzuki S, Yoshihisa A, Yokokawa T, Kobayashi A, Yamaki T, Kunii H, Nakazato K, Tsuda A, Tsuda T, Ishibashi T, Konno I, Yamaguchi O, Machii H, Nozaki N, Niizeki T, Miyamoto T, Takeishi Y. Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial. J Int Med Res2021;49:1–15.
Not in our library10.1177/03000605211062770
61.
MacKenzie IS, Ford I, Walker A, Hawkey C, Begg A, Avery A, Taggar J, Wei L, Struthers AD, MacDonald TM. Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study. BMJ Open2016;6:e013774.
Not in our library10.1136/bmjopen-2016-013774
62.
Edelmann F, Holzendorf V, Wachter R, Nolte K, Schmidt AG, Kraigher-Krainer E, Duvinage A, Unkelbach I, Düngen HD, Tschöpe C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Stough WG, Pieske BM. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the aldo-DHF trial. Eur J Heart Fail2015;17:214–223.
Not in our library10.1002/ejhf.203
63.
van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, Muntendam P, van Veldhuisen DJ, de Boer RA. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail2013;6:219–226.
Not in our library10.1161/circheartfailure.112.000129
64.
Calvier L, Martinez-Martinez E, Miana M, Cachofeiro V, Rousseau E, Sádaba JR, Zannad F, Rossignol P, López-Andrés N. The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Hear Fail2015;3:59–67.
Not in our library10.1016/j.jchf.2014.08.002
65.
Cunningham JW, Claggett BL, O’Meara E, Prescott MF, Pfeffer MA, Shah SJ, Redfield MM, Zannad F, Chiang L-M, Rizkala AR, Shi VC, Lefkowitz MP, Rouleau J, McMurray JJ V, Solomon SD, Zile MR. Effect of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with HFpEF. J Am Coll Cardiol2020;76:503–514.
Not in our library10.1016/j.jacc.2020.05.072
66.
Rios FJ, Zou ZG, Harvey AP, Harvey KY, Nosalski R, Anyfanti P, Camargo LL, Lacchini S, Ryazanov AG, Ryazanova L, McGrath S, Guzik TJ, Goodyear CS, Montezano AC, Touyz RM. Chanzyme TRPM7 protects against cardiovascular inflammation and fibrosis. Cardiovasc Res2020;116:721–735.
Not in our library10.1093/cvr/cvz164
67.
Frangogiannis NG. Cardiac fibrosis. Cardiovasc Res2021;117:1450–1488.
Not in our library10.1093/cvr/cvaa324
68.
Cleland JGF, Ferreira JP, Mariottoni B, Pellicori P, Cuthbert J, Verdonschot JAJ, Petutschnigg J, Ahmed FZ, Cosmi F, Brunner La Rocca H-P, Mamas MA, Clark AL, Edelmann F, Pieske B, Khan J, McDonald K, Rouet P, Staessen JA, Mujaj B, González A, Diez J, Hazebroek M, Heymans S, Latini R, Grojean S, Pizard A, Girerd N, Rossignol P, Collier TJ, Zannad F. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial. Eur Heart J2021;42:684–696.
Not in our library10.1093/eurheartj/ehaa758
69.
Pellicori P, Ferreira JP, Mariottoni B, Brunner-La Rocca HP, Ahmed FZ, Verdonschot J, Collier T, Cuthbert JJ, Petutschnigg J, Mujaj B, Girerd N, González A, Clark AL, Cosmi F, Staessen JA, Heymans S, Latini R, Rossignol P, Zannad F, Cleland JGF. Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The heart OMics in AGing (HO). Eur J Heart Fail2020;22:1711–1723.
Not in our library10.1002/ejhf.1716
70.
Zhao B, Bouchareb R, Lebeche D. Resistin deletion protects against heart failure injury by targeting DNA damage response. Cardiovasc Res2021. Epub ahead of print 29 July 2021.
Not in our library10.1093/cvr/cvab234
71.
Masini G, Graham FJ, Pellicori P, Cleland JGF, Cuthbert JJ, Kazmi S, Inciardi RM, Clark AL. Criteria for iron deficiency in patients with heart failure. J Am Coll Cardiol2022;79:341–351.
Not in our library10.1016/j.jacc.2021.11.039
72.
Cleland JGF, Zhang J, Pellicori P, Dicken B, Dierckx R, Shoaib A, Wong K, Rigby A, Goode K, Clark AL. Prevalence and outcomes of anemia and hematinic deficiencies in patients with chronic heart failure. JAMA Cardiol2016;1:539–547.
Not in our library10.1001/jamacardio.2016.1161
73.
Anand IS, Gupta P. Anemia and iron deficiency in heart failure: current concepts and emerging therapies. Circulation2018;138:80–98.
Not in our library10.1161/circulationaha.118.030099
74.
Graham FJ, Pellicori P, Ford I, Petrie MC, Kalra PR, Cleland JGF. Intravenous iron for heart failure with evidence of iron deficiency: a meta-analysis of randomised trials. Clin Res Cardiol2021;110:1299–1307.
Not in our library10.1007/s00392-021-01837-8
75.
Gladka MM. Single-Cell RNA sequencing of the adult mammalian heart—state-of-the-art and future perspectives. Curr Heart Fail Rep2021;18:64–70.
Not in our library10.1007/s11897-021-00504-3
76.
Vallejo J, Cochain C, Zernecke A, Ley K. Heterogeneity of immune cells in human atherosclerosis revealed by scRNA-seq. Cardiovasc Res2021;117:2537–2543.
Not in our library10.1093/cvr/cvab260
77.
Mitter SS, Shah SJ, Thomas JD. A test in context: E/A and E/e′ to assess diastolic dysfunction and LV filling pressure. J Am Coll Cardiol2017;69:1451–1464.
Not in our library10.1016/j.jacc.2016.12.037
78.
Reddy YNV, Obokata M, Egbe A, Yang JH, Pislaru S, Lin G, Carter R, Borlaug BA. Left atrial strain and compliance in the diagnostic evaluation of heart failure with preserved ejection fraction. Eur J Heart Fail2019;21:891–900.
Not in our library10.1002/ejhf.1464
79.
Pugliese NR, De Biase N, Conte L, Gargani L, Mazzola M, Fabiani I, Natali A, Dini FL, Frumento P, Rosada J, Taddei S, Borlaug BA, Masi S. Cardiac reserve and exercise capacity: insights from combined cardiopulmonary and exercise echocardiography stress testing. J Am Soc Echocardiogr2021;34:38–50.
Not in our library10.1016/j.echo.2020.08.015
80.
Iacobellis G, Willens HJ. Echocardiographic epicardial fat: a review of research and clinical applications. J Am Soc Echocardiogr2009;22:1311–1319.
Not in our library10.1016/j.echo.2009.10.013
81.
Pugliese NR, Paneni F, Mazzola M, De Biase N, Del Punta L, Gargani L, Mengozzi A, Virdis A, Nesti L, Taddei S, Flammer A, Borlaug BA, Ruschitzka F, Masi S. Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure. Eur J Heart Fail2021;23:1858–1871.
Not in our library10.1002/ejhf.2337
82.
Pellicori P, Platz E, Dauw J, ter Maaten JM, Martens P, Pivetta E, Cleland JGF, McMurray JJV, Mullens W, Solomon SD, Zannad F, Gargani L, Girerd N. Ultrasound imaging of congestion in heart failure: examinations beyond the heart. Eur J Heart Fail2021;23:703–712.
Not in our library10.1002/ejhf.2032
83.
Inflammation – Cause or Consequence of Heart Failure or Both? · 2017
No notice
84.
Colombo PC, Onat D, Harxhi A, Demmer RT, Hayashi Y, Jelic S, Lejemtel TH, Bucciarelli L, Kebschull M, Papapanou P, Uriel N, Schmidt AM, Sabbah HN, Jorde UP. Peripheral venous congestion causes inflammation, neurohormonal, and endothelial cell activation. Eur Heart J2014;35:448–454.
Not in our library10.1093/eurheartj/eht456
85.
Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, Poole-Wilson PA, Andrew J, Coats S, Anker SD. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet1999;353:1838–1842.
Not in our library10.1016/s0140-6736(98)09286-1
86.
Kim M, Huda MN, Bennett BJ. Sequence meets function—microbiota and cardiovascular disease. Cardiovasc Res2022;118:399–412.
Not in our library10.1093/cvr/cvab030
87.
Tromp J, Bryant JA, Jin X, van Woerden G, Asali S, Yiying H, Liew OW, Ching JCP, Jaufeerally F, Loh SY, Sim D, Lee S, Soon D, Tay WT, Packer M, van Veldhuisen DJ, Chin C, Richards AM, Lam CSP. Epicardial fat in heart failure with reduced versus preserved ejection fraction. Eur J Heart Fail2021;23:835–838.
Not in our library10.1002/ejhf.2156
88.
Van Woerden G, Van Veldhuisen DJ, Manintveld OC, Van Empel VPM, Willems TP, De Boer RA, Rienstra M, Westenbrink BD, Gorter TM. Epicardial adipose tissue and outcome in heart failure with mid-range and preserved ejection fraction. Circ Heart Fail2022;15:E009238.
Not in our library10.1161/circheartfailure.121.009238
89.
Nagueh SF, Chang SM, Nabi F, Shah DJ, Estep JD. Cardiac imaging in patients with heart failure and preserved ejection fraction. Circ Cardiovasc Imaging2017;10. Epub ahead of print 1 August 2017.
Not in our library10.1161/circimaging.117.006547
90.
Cuijpers I, Simmonds SJ, van Bilsen M, Czarnowska E, González Miqueo A, Heymans S, Kuhn AR, Mulder P, Ratajska A, Jones EAV, Brakenhielm E. Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities. Basic Res Cardiol2020;115:1–15.
Not in our library10.1007/s00395-020-0798-y
91.
Thackeray JT, Bengel FM. Molecular imaging of myocardial inflammation with positron emission tomography post-ischemia: a determinant of subsequent remodeling or recovery. JACC Cardiovas Imaging2018;11:1340–1355.
Not in our library10.1016/j.jcmg.2018.05.026
92.
Liberale L, Montecucco F, Schwarz L, Lüscher TF, Camici GG. Inflammation and cardiovascular diseases: lessons from seminal clinical trials. Cardiovasc Res2021;117:411–422.
Not in our library10.1093/cvr/cvaa211
93.
Tardif JC, McMurray JJ, Klug E, Small R, Schumi J, Choi J, Cooper J, Scott R, Lewis EF, L’Allier PL, Pfeffer MA. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet2008;371:1761–1768.
Not in our library10.1016/s0140-6736(08)60763-1
94.
Moreira DM, Vieira JL, Mascia Gottschall CA. The effects of METhotrexate therapy on the physical capacity of patients with ISchemic heart failure: a randomized double-blind, placebo-controlled trial (METIS trial). J Card Fail2009;15:828–834.
Not in our library10.1016/j.cardfail.2009.06.439
95.
Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, Mam V, Hasan A, Rosenberg Y, Iturriaga E, Gupta M, Tsigoulis M, Verma S, Clearfield M, Libby P, Goldhaber SZ, Seagle R, Ofori C, Saklayen M, Butman S, Singh N, May ML, Bertrand O, Johnston J, Paynter NP, Glynn RJ. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med2019;380:752–762.
Not in our library10.1056/nejmoa1809798
96.
Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol2013;61:404–410.
Not in our library10.1016/j.jacc.2012.10.027
97.
Tardif J-C, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, Berry C, López-Sendón J, Ostadal P, Koenig W, Angoulvant D, Grégoire JC, Lavoie M-A, Dubé M-P, Rhainds D, Provencher M, Blondeau L, Orfanos A, L’Allier PL, Guertin M-C, Roubille F. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med2019;381:2497–2505.
Not in our library10.1056/nejmoa1912388
98.
Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, The SHK, Xu X-F, Ireland MA, Lenderink T, Latchem D, Hoogslag P, Jerzewski A, Nierop P, Whelan A, Hendriks R, Swart H, Schaap J, Kuijper AFM, van Hessen MWJ, Saklani P, Tan I, Thompson AG, Morton A, Judkins C, Bax WA, Dirksen M, Alings M, Hankey GJ, Budgeon CA. Colchicine in patients with chronic coronary disease. N Engl J Med2020;383:1838–1847.
Not in our library10.1056/nejmoa2021372
99.
Tong DC, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, Adams H, Sriamareswaran R, Htun NM, Wilson W, Stub D, van Gaal W, Howes L, Collins N, Yong A, Bhindi R, Whitbourn R, Lee A, Hengel C, Asrress K, Freeman M, Amerena J, Wilson A, Layland J. Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial. Circulation2020;142:1890–1900.
Not in our library10.1161/circulationaha.120.050771
100.
O’Donoghue ML, Braunwald E, White HD, Steen DP, Lukas MA, Tarka E, Steg PG, Hochman JS, Bode C, Maggioni AP, Im KA, Shannon JB, Davies RY, Murphy SA, Crugnale SE, Wiviott SD, Bonaca MP, Watson DF, Weaver WD, Serruys PW, Cannon CP, Steen DP, Lamp JM, McCourt A, Barakat D, Mezzetti J, Morrison C, Stevens M, Ward C, Ardissino D. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. J Am Med Assoc2014;312:1006–1015.
Not in our library10.1001/jama.2014.11061
101.
Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med2014; 370:1702–1711.
Not in our library10.1056/nejmoa1315878
102.
Nicholls SJ, Kastelein JJP, Schwartz GG, Bash D, Rosenson RS, Cavender MA, Brennan DM, Koenig W, Jukema JW, Nambi V, Wright RS, Menon V, Lincoff AM, Nissen SE, Hennekens C, Brown W V, DeMets D, Pfeffer M, Roleau J, Abraham J, Gebel J, Huff C, Katzan I, Shishehbor M, Rassi A, Uchino K, Vest A, Zishiri E, Heckman MJ, Balog C. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. J Am Med Assoc2014;311:252–262.
Not in our library10.1001/jama.2013.282836
103.
Tardif JC, Pfeffer MA, Kouz S, Koenig W, Maggioni AP, McMurray JJ V, Mooser V, Waters DD, Grégoire JC, L’Allier PL, Jukema WJ, White HD, Heinonen T, Black DM, Laghrissi-Thode F, Levesque S, Guertin MC, Dubé MP. Investigators for the dal-G. Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial. Eur Heart J2022.
Not in our library10.1093/eurheartj/ehac374
104.
Morton AC, Rothman AMK, Greenwood JP, Gunn J, Chase A, Clarke B, Hall AS, Fox K, Foley C, Banya W, Wang D, Flather MD, Crossman DC. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA heart study. Eur Heart J2015;36:377–384.
Not in our library10.1093/eurheartj/ehu272
105.
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med2017;377:1119–1131.
Not in our library10.1056/nejmoa1707914
106.
Everett BM, Cornel JH, Lainscak M, Anker SD, Abbate A, Thuren T, Libby P, Glynn RJ, Ridker PM. Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure. Circulation2019;139:1289–1299.
Not in our library10.1161/circulationaha.118.038010
107.
Interleukin‐1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST‐Segment–Elevation Myocardial Infarction · 2020
Not checked
108.
Fröbert O, Götberg M, Erlinge D, Akhtar Z, Christiansen EH, MacIntyre CR, Oldroyd KG, Motovska Z, Erglis A, Moer R, Hlinomaz O, Jakobsen L, Engstrøm T, Jensen LO, Fallesen CO, Jensen SE, Angerås O, Calais F, Kåregren A, Lauermann J, Mokhtari A, Nilsson J, Persson J, Stalby P, Islam AKMM, Rahman A, Malik F, Choudhury S, Collier T, Pocock SJ. Influenza vaccination after myocardial infarction: a randomized, double-blind, placebo-controlled, multicenter trial. Circulation2021;144:1476–1484.
Not in our library10.1161/circulationaha.121.057042
109.
Loeb M, Dokainish H, Dans A, Palileo-Villanueva LM, Roy A, Karaye K, Zhu J, Liang Y, Goma F, Damasceno A, AlHabib KF, Yonga G, Mondo C, Almahmeed W, Al Mulla A, Yusuf S. Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): rationale and design. Am Heart J Mosby2019;212:36–44.
Not in our library10.1016/j.ahj.2019.02.009
110.
Nicholls SJ, Schwartz GG, Buhr KA, Ginsberg HN, Johansson JO, Kalantar-Zadeh K, Kulikowski E, Toth PP, Wong N, Sweeney M, Ray KK. Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study. Cardiovasc Diabetol2021;20. Epub ahead of print 2021.
Not in our library10.1186/s12933-020-01199-x
111.
Rush CJ, Berry C, Oldroyd KG, Rocchiccioli JP, Lindsay MM, Touyz RM, Murphy CL, Ford TJ, Sidik N, McEntegart MB, Lang NN, Jhund PS, Campbell RT, McMurray JJV, Petrie MC. Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. JAMA Cardiol2021;6:1130–1143.
Not in our library10.1001/jamacardio.2021.1825
112.
Taqueti VR. Coronary microvascular dysfunction in heart failure with preserved ejection fraction – common, unrecognized, and prevalent in patients with or without epicardial cad. JAMA Cardiol2021;6:1118–1120.
Not in our library10.1001/jamacardio.2021.1832
113.
Mordi IR, Pearson ER, Palmer CNA, Doney ASF, Lang CC. Differential association of genetic risk of coronary artery disease with development of heart failure with reduced versus preserved ejection fraction: a GoDARTS Mendelian randomization study and meta-analysis. Circulation2019;139:986–988.
Not in our library10.1161/circulationaha.118.038602
114.
Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect? · 2017
No notice
115.
Recio-Mayoral A, Mason JC, Kaski JC, Rubens MB, Harari OA, Camici PG. Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. Eur Heart J2009;30:1837–1843.
Not in our library10.1093/eurheartj/ehp205
116.
Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH). Circulation2003;107:3133–3140.
Not in our library10.1161/01.cir.0000077913.60364.d2
117.
Mann DL, McMurray JJV, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, Van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T. Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL). Circulation2004;109:1594–1602.
Not in our library10.1161/01.cir.0000124490.27666.b2
118.
Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JGF, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson Å, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJV, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J. Rosuvastatin in older patients with systolic heart failure. N Engl J Med2007;357:2248–2261.
Not in our library10.1056/nejmoa0706201
119.
GISSI-HF investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet2008;372:1231–1239.
Not in our library10.1016/s0140-6736(08)61240-4
120.
Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, LeWinter MM, Joseph SM, Shah SJ, Semigran MJ, Felker GM, Cole RT, Reeves GR, Tedford RJ, Tang WHW, McNulty SE, Velazquez EJ, Shah MR, Braunwald E. Isosorbide mononitrate in heart failure with preserved ejection fraction. N Engl J Med2015;373:2314–2324.
Not in our library10.1056/nejmoa1510774
121.
Pieske B, Maggioni AP, Lam CSP, Pieske-Kraigher E, Filippatos G, Butler J, Ponikowski P, Shah SJ, Solomon SD, Scalise AV, Mueller K, Roessig L, Gheorghiade M. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J2017;38:1119–1127.
Not in our library10.1093/eurheartj/ehw593
122.
Borlaug BA, Anstrom KJ, Lewis GD, Shah SJ, Levine JA, Koepp GA, Givertz MM, Felker GM, Lewinter MM, Mann DL, Margulies KB, Smith AL, Tang WHW, Whellan DJ, Chen HH, Davila-Roman VG, McNulty S, Desvigne-Nickens P, Hernandez AF, Braunwald E, Redfield MM. Effect of inorganic nitrite vs placebo on exercise capacity among patients with heart failure with preserved ejection fraction: the INDIE-HFpEF randomized clinical trial. J Am Med Assoc2018;320:1764–1773.
Not in our library10.1001/jama.2018.14852
123.
Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O’Connor CM. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med2020;382:1883–1893.
Not in our library10.1056/nejmoa1915928
124.
Armstrong PW, Lam CSP, Anstrom KJ, Ezekowitz J, Hernandez AF, O’Connor CM, Pieske B, Ponikowski P, Shah SJ, Solomon SD, Voors AA, She L, Vlajnic V, Carvalho F, Bamber L, Blaustein RO, Roessig L, Butler J. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial. J Am Med Assoc2020;324:1512–1521.
Not in our library10.1001/jama.2020.15922
125.
Deftereos S, Giannopoulos G, Panagopoulou V, Bouras G, Raisakis K, Kossyvakis C, Karageorgiou S, Papadimitriou C, Vastaki M, Kaoukis A, Angelidis C, Pagoni S, Pyrgakis V, Alexopoulos D, Manolis AS, Stefanadis C, Cleman MW. Anti-inflammatory treatment with colchicine instable chronic heart failure. A prospective, randomized study. JACC Hear Fail2014;2:131–137.
Not in our library10.1016/j.jchf.2013.11.006
126.
Van Tassell BW, Arena R, Biondi-Zoccai G, McNair Canada J, Oddi C, Abouzaki NA, Jahangiri A, Falcao RA, Kontos MC, Shah KB, Voelkel NF, Dinarello CA, Abbate A. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol2014;113:321–327.
Not in our library10.1016/j.amjcard.2013.08.047
127.
Van Tassell BW, Trankle CR, Canada JM, Carbone S, Buckley L, Kadariya D, Del Buono MG, Billingsley H, Wohlford G, Viscusi M, Oddi-Erdle C, Abouzaki NA, Dixon D, Biondi-Zoccai G, Arena R, Abbate A. IL-1 blockade in patients with heart failure with preserved ejection fraction. Circ Heart Fail2018;11:e005036.
Not in our library10.1161/circheartfailure.118.005036
128.
Van Tassell BW, Canada J, Carbone S, Trankle C, Buckley L, Erdle CO, Abouzaki NA, Dixon D, Kadariya D, Christopher S, Schatz A, Regan J, Viscusi M, Del BM, Melchior R, Mankad P, Lu J, Sculthorpe R, Biondi-Zoccai G, Lesnefsky E, Arena R, Abbate A. Interleukin-1 blockade in recently decompensated systolic heart failure: results from REDHART (recently decompensated heart failure anakinra response trial). Circ Hear Fail2017;10.
Not in our library10.1161/circheartfailure.117.004373
129.
Trankle CR, Canada JM, Cei L, Abouzaki N, Oddi-Erdle C, Kadariya D, Christopher S, Viscusi M, Del Buono M, Kontos MC, Arena R, Van Tassell B, Abbate A. Usefulness of canakinumab to improve exercise capacity in patients with long-term systolic heart failure and elevated C-reactive protein. Am J Cardiol2018;122:1366–1370.
Not in our library10.1016/j.amjcard.2018.07.002
130.
McMurray J, Solomon S, Inzucchi S, Køber L, Kosiborod M, Martinez F, Ponikowski P, Sabatine M, Anand I, Bělohlávek J, Böhm M, Chiang C, Chopra V, de Boer R, Desai A, Diez M, Drozdz J, Dukát A, Ge J, Howlett J, Investigators D-HTC. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med2019;381:1995–2008.
Not in our library10.1056/nejmoa1911303
131.
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi D-J, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca H-P, Merkely B, Nicholls SJ, Perrone S, Pina I. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med2020;383:1413–1424.
Not in our library10.1056/nejmoa2022190
132.
Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Verma S, Lapuerta P, Pitt B. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med2021;384:117–128.
Not in our library10.1056/nejmoa2030183
133.
Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov2005;4:977–987.
Not in our library10.1038/nrd1901
134.
Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AMJ, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med2008;359:2195–2207.
Not in our library10.1056/nejmoa0807646
135.
GISSI-HF investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet2008;372:1223–1230.
Not in our library10.1016/s0140-6736(08)61239-8
136.
Cleland JGF, McMurray JJV, Kjekshus J, Cornel JH, Dunselman P, Fonseca C, Hjalmarson Å, Korewicki J, Lindberg M, Ranjith N, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin. A report from CORONA (controlled rosuvastatin multinational trial in heart). J Am Coll Cardiol2009;54:1850–1859.
Not in our library10.1016/j.jacc.2009.06.041
137.
Cleland JGF, Squire I, Ng L. Interpretation of amino-terminal pro-brain natriuretic peptide levels in the HPS and the CORONA study. J Am Coll Cardiol2008;52:1104–1105.
Not in our library10.1016/j.jacc.2008.04.070
138.
The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials · 2015
No notice
139.
Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation2007;115:1285–1295.
Not in our library10.1161/circulationaha.106.652859
140.
Farah C, Michel LYM, Balligand JL. Nitric oxide signalling in cardiovascular health and disease. Nat Rev Cardiol2018;15:292–316.
Not in our library10.1038/nrcardio.2017.224
141.
Hamdani N, Bishu KG, Von Frieling-Salewsky M, Redfield MM, Linke WA. Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction. Cardiovasc Res2013;97:464–471.
Not in our library10.1093/cvr/cvs353
142.
Van Heerebeek L, Franssen CPM, Hamdani N, Verheugt FWA, Somsen GA, Paulus WJ. Molecular and cellular basis for diastolic dysfunction. Curr Heart Fail Rep2012;9:293–302.
Not in our library10.1007/s11897-012-0109-5
143.
Sharma JN, Al-Omran A, Parvathy SS. Role of nitric oxide in inflammatory diseases. Inflammopharmacology2007;15:252–259.
Not in our library10.1007/s10787-007-0013-x
144.
Yamamoto E, Hirata Y, Tokitsu T, Kusaka H, Sakamoto K, Yamamuro M, Kaikita K, Watanabe H, Hokimoto S, Sugiyama S, Maruyama T, Ogawa H. The pivotal role of eNOS uncoupling in vascular endothelial dysfunction in patients with heart failure with preserved ejection fraction. Int J Cardiol2015;190:335–337.
Not in our library10.1016/j.ijcard.2015.04.162
145.
Felker GM, McMurray JJV, Cleland JG, O'Connor CM, Teerlink JR, Voors AA, Belohlavek J, B M, Borentain M, Bueno H, Cole RT, DeSouza MM, Ezekowitz JA, Filippatos G, Lang NN, Kessler PD, Martinez FA, Mebazaa A, Metra M, Mosterd A, Pang PS, Ponikowski P, Sato N, Seiffert D, Ye J. Effects of a novel nitroxyl donor in acute heart failure: the STAND-UP AHF study. JACC Hear Fail2021;9:146–157.
Not in our library10.1016/j.jchf.2020.10.012
146.
Lang NN, Ahmad FA, Cleland JG, O'Connor CM, Teerlink JR, Voors AA, Taubel J, Hodes AR, Anwar M, Karra R, Sakata Y, Ishihara S, Senior R, Khemka A, Prasad NG, DeSouza MM, Seiffert D, Ye JY, Kessler PD, Borentain M, Solomon SD, Felker GM, McMurray JJV. Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trial. Eur J Heart Fail2021;23:1147–1155.
Not in our library10.1002/ejhf.2138
147.
Andreu JM, Timasheff SN. Tubulin bound to colchicine forms polymers different from microtubules. Proc Natl Acad Sci U S A1982;79:6753–6756.
Not in our library10.1073/pnas.79.22.6753
148.
Cronstein BN, Molad Y, Reibman J, Balakhane E, Levin RI, Weissmann G. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest1995;96:994–1002.
Not in our library10.1172/jci118147
149.
Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR, Aunins J, Elliston KO, Ayala JM, Casano FJ, Chin J, Ding GJF, Egger LA, Gaffney EP, Limjuco G, Palyha OC, Raju SM, Rolando AM, Salley JP, Yamin TT, Lee TD, Shively JE, MacCross M, Mumford RA, Schmidt JA, Tocci MJ. A novel heterodimeric cysteine protease is required for interleukin-1β processing in monocytes. Nature1992;356:768–774.
Not in our library10.1038/356768a0
150.
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med1997;336:973–979.
Not in our library10.1056/nejm199704033361401
151.
Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation1998;98:731–733.
Not in our library10.1161/01.cir.98.8.731
152.
Chia YC, Kieneker LM, van Hassel G, Binnenmars SH, Nolte IM, van Zanden JJ, van der Meer P, Navis G, Voors AA, Bakker SJL, De Borst MH, Eisenga MF. Interleukin 6 and development of heart failure with preserved ejection fraction in the general population. J Am Heart Assoc2021;10:18549.
Not in our library10.1161/jaha.120.018549
153.
Van Tassell BW, Raleigh JMV, Abbate A. Targeting interleukin-1 in heart failure and inflammatory heart disease. Curr Heart Fail Rep2015;12:33–41.
Not in our library10.1007/s11897-014-0231-7
154.
De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, Koné-Paut I, Lachmann HJ, Ozen S, Simon A, Zeft A, Calvo Penades I, Moutschen M, Quartier P, Kasapcopur O, Shcherbina A, Hofer M, Hashkes PJ, Van der Hilst J, Hara R, Bujan-Rivas S, Constantin T, Gul A, Livneh A, Brogan P, Cattalini M, Obici L, Lheritier K, Speziale A, Junge G. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med2018;378:1908–1919.
Not in our library10.1056/nejmoa1706314
155.
Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol2009;36:1118–1125.
Not in our library10.3899/jrheum.090074
156.
Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease · 2019
No notice
157.
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus · 2018
No notice
158.
Solomon SD, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Lindholm D, Wilderäng U, Öhrn F, Claggett B, Langkilde AM, Petersson M, McMurray JJV. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. Eur J Heart Fail2021;23:1217–1225.
Not in our library10.1002/ejhf.2249
159.
Savarese G, Butler J, Lund LH, Bhatt DL, Anker SD. Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms. Cardiovasc Res2021. Epub ahead of print 15 August 2021.
Not in our library10.1093/cvr/cvab271
160.
Garvey WT, Van Gaal L, Leiter LA, Vijapurkar U, List J, Cuddihy R, Ren J, Davies MJ. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metab Clin Exp2018;85:32–37.
Not in our library10.1016/j.metabol.2018.02.002
161.
The effect of dapagliflozin treatment on epicardial adipose tissue volume · 2018
No notice
162.
Iborra-Egea O, Santiago-Vacas E, Yurista SR, Lupón J, Packer M, Heymans S, Zannad F, Butler J, Pascual-Figal D, Lax A, Núñez J, de Boer RA, Bayés-Genís A. Unraveling the molecular mechanism of action of empagliflozin in heart failure with reduced ejection fraction with or without diabetes. JACC Basic Transl Sci2019;4:831–840.
Not in our library10.1016/j.jacbts.2019.07.010
163.
Cowie MR, Fisher M. SGLT2 Inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol2020;17:761–772.
Not in our library10.1038/s41569-020-0406-8
164.
Packer M. Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress. Cardiovasc Res2021;117:74–84.
Not in our library10.1093/cvr/cvaa064
165.
Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart · 2020
No notice
166.
Chung YJ, Park KC, Tokar S, Eykyn TR, Fuller W, Pavlovic D, Swietach P, Shattock MJ. SGLT2 Inhibitors and the cardiac Na+/H+ exchanger-1: the plot thickens. Cardiovasc Res2021;117:2702–2704.
Not in our library10.1093/cvr/cvab184
167.
SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart · 2019
No notice
168.
Decoding empagliflozin’s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence · 2021
Not checked
169.
Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S, Macaluso F, Sartori S, Roque M, Sabatel-Perez F, Rodriguez-Cordero A, Zafar MU, Fergus I, Atallah-Lajam F, Contreras JP, Varley C, Moreno PR, Abascal VM, Lala A, Tamler R, Sanz J, Fuster V, Badimon JJ. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol2021;77:243–255.
Not in our library10.1016/j.jacc.2020.11.008
170.
Antonio R-IJ GS-GC, Anderly R-C PV-DA, Donna M, Samantha S, Farah A-L, Chiara G, Frank M, Anuradha L, Javier S, Valentin F, José BJ. Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF. JACC Hear Fail2021;9:578–589.
Not in our library10.1016/j.jchf.2021.04.014
171.
Stark K, Massberg S. Interplay between inflammation and thrombosis in cardiovascular pathology. Nat Rev Cardiol2021;18:666–682.
Not in our library10.1038/s41569-021-00552-1
172.
Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, St S, Keltai M, Ryden L, Pogosova N. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med2017;377:1319–1330.
Not in our library10.1056/nejmoa1709118
173.
Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade M, Lam CSP, Mehra MR, Neaton JD, Nessel CC, Spiro TE, van Veldhuisen DJ, Greenberg B. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med2018;379:1332–1342.
Not in our library10.1056/nejmoa1808848
174.
Cleland JGF, Pellicori P. Myocardial dysfunction and coronary artery disease as therapeutic targets in heart failure COMPASS directions. Circulation2019;140:538–541.
Not in our library10.1161/circulationaha.119.041523
175.
Modin D, Jørgensen ME, Gislason G, Jensen JS, Køber L, Claggett B, Hegde SM, Solomon SD, Torp-Pedersen C, Biering-Sørensen T. Influenza vaccine in heart failure: cumulative number of vaccinations, frequency, timing, and survival: a Danish nationwide cohort study. Circulation2019;139:575–586.
Not in our library10.1161/circulationaha.118.036788
176.
Association of Influenza Vaccination With Cardiovascular Risk · 2022
No notice
177.
Johnson KW, Patel S, Thapi S, Jaladanki BS SK, Rao A, Nirenberg S, Lala A. Association of reduced hospitalizations and mortality among COVID-19 vaccinated patients with heart failure. J Card Fail2022. Epub ahead of print June 2022.
Not in our library10.1016/j.cardfail.2022.05.008
178.
Pellicori P, Khan MJI, Graham FJ, Cleland JGF. New perspectives and future directions in the treatment of heart failure. Heart Fail Rev2020;25:147–159.
Not in our library10.1007/s10741-019-09829-7
179.
Ridker PM, Libby P, MacFadyen JG, Thuren T, Ballantyne C, Fonseca F, Koenig W, Shimokawa H, Everett BM, Glynn RJ. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS). Eur Heart J2018;39:3499–3507.
Not in our library10.1093/eurheartj/ehy310
180.
Liberale L, Montecucco F, Tardif JC, Libby P, Camici GG. Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease. Eur Heart J2020;41:2974–2982.
Not in our library10.1093/eurheartj/ehz961
181.
Kosmopoulos M, Chiriacò M, Stamatelopoulos K, Tsioufis C, Masci PG, Kontogiannis C, Mengozzi A, Pugliese NR, Taddei S, Virdis A, Masi S, Georgiopoulos G. The relationship between telomere length and putative markers of vascular ageing: a systematic review and meta-analysis. Mech Ageing Dev2021;201:111604.
Not in our library10.1016/j.mad.2021.111604
182.
Tyrrell DJ, Goldstein DR. Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6. Nat Rev Cardiol2020;18:58–68.
Not in our library10.1038/s41569-020-0431-7
183.
Markousis-Mavrogenis G, Tromp J, Ouwerkerk W, Devalaraja M, Anker SD, Cleland JG, Dickstein K, Filippatos GS, van der Harst P, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, Zannad F, Zwinderman AH, Hillege HL, van Veldhuisen DJ, Kakkar R, Voors AA, van der Meer P. The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study. Eur J Heart Fail2019;21:965–973.
Not in our library10.1002/ejhf.1482
184.
Meléndez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower GL. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertens (Dallas, Tex 1979)2010;56:225–231.
Not in our library10.1161/hypertensionaha.109.148635
185.
Kobayashi H, Kobayashi Y, Giles JT, Yoneyama K, Nakajima Y, Takei M. Tocilizumab treatment increases left ventricular ejection fraction and decreases left ventricular mass index in patients with rheumatoid arthritis without cardiac symptoms: assessed using 3.0 tesla cardiac magnetic resonance imaging. J Rheumatol2014;41:1916–1921.
Not in our library10.3899/jrheum.131540
186.
Broch K, Anstensrud AK, Woxholt S, Sharma K, Tøllefsen IM, Bendz B, Aakhus S, Ueland T, Amundsen BH, Damås JK, Berg ES, Bjørkelund E, Bendz C, Hopp E, Kleveland O, Stensæth KH, Opdahl A, Kløw NE, Seljeflot I, Andersen GØ, Wiseth R, Aukrust P, Gullestad L. Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction. J Am Coll Cardiol2021;77:1845–1855.
Not in our library10.1016/j.jacc.2021.02.049
187.
Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, Lo L, Kling D, Pergola P, Raj D, Libby P, Davidson M. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet2021;397:2060–2069.
Not in our library10.1016/s0140-6736(21)00520-1
188.
Bajpai G, Bredemeyer A, Li W, Zaitsev K, Koenig AL, Lokshina I, Mohan J, Ivey B, Hsiao HM, Weinheimer C, Kovacs A, Epelman S, Artyomov M, Kreisel D, Lavine KJ. Tissue resident CCR2- and CCR2+ cardiac macrophages differentially orchestrate monocyte recruitment and fate specification following myocardial injury. Circ Res2019;124:263–278.
Not in our library10.1161/circresaha.118.314028
189.
Bajpai G, Schneider C, Wong N, Bredemeyer A, Hulsmans M, Nahrendorf M, Epelman S, Kreisel D, Liu Y, Itoh A, Shankar TS, Selzman CH, Drakos SG, Lavine KJ. The human heart contains distinct macrophage subsets with divergent origins and functions. Nat Med2018;24:1234–1245.
Not in our library10.1038/s41591-018-0059-x
190.
Patel B, Bansal SS, Ismahil MA, Hamid T, Rokosh G, Mack M, Prabhu SD. CCR2+ monocyte-derived infiltrating macrophages are required for adverse cardiac remodeling during pressure overload. JACC Basic Transl Sci2018;3:230–244.
Not in our library10.1016/j.jacbts.2017.12.006
191.
Haudek SB, Cheng J, Du J, Wang Y, Hermosillo-Rodriguez J, Trial JA, Taffet GE, Entman ML. Monocytic fibroblast precursors mediate fibrosis in angiotensin-II-induced cardiac hypertrophy. J Mol Cell Cardiol2010;49:499–507.
Not in our library10.1016/j.yjmcc.2010.05.005
192.
Gilbert J, Lekstrom-Himes J, Donaldson D, Lee Y, Hu M, Xu J, Wyant T, Davidson M. Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region. Am J Cardiol2011;107:906–911.
Not in our library10.1016/j.amjcard.2010.11.005
193.
Gallet R, de Couto G, Simsolo E, Valle J, Sun B, Liu W, Tseliou E, Zile MR, Marbán E. Cardiosphere-derived cells reverse heart failure with preserved ejection fraction in rats by decreasing fibrosis and inflammation. JACC Basic Transl Sci2016;1:14–28.
Not in our library10.1016/j.jacbts.2016.01.003
194.
Pugliese NR, De Biase N, Gargani L, Mazzola M, Conte L, Fabiani I, Natali A, Dini FL, Frumento P, Rosada J, Taddei S, Borlaug BA, Masi S. Predicting the transition to and progression of heart failure with preserved ejection fraction: a weighted risk score using bio-humoural, cardiopulmonary, and echocardiographic stress testing. Eur J Prev Cardiol2021;28:1650–1661.
Not in our library10.1093/eurjpc/zwaa129
195.
Del Buono MG, Arena R, Borlaug BA, Carbone S, Canada JM, Kirkman DL, Garten R, Rodriguez-Miguelez P, Guazzi M, Lavie CJ, Abbate A. Exercise intolerance in patients with heart failure: JACC state-of-the-art review. J Am Coll Cardiol2019;73:2209–2225.
Not in our library10.1016/j.jacc.2019.01.072
196.
Kitzman DW, Brubaker PH, Herrington DM, Morgan TM, Stewart KP, Hundley WG, Abdelhamed A, Haykowsky MJ. Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. J Am Coll Cardiol2013;62:584–592.
Not in our library10.1016/j.jacc.2013.04.033
197.
Mann N, Rosenzweig A. Can exercise teach US how to treat heart disease?Circulation2012;126:2625–2635.
Not in our library10.1161/circulationaha.111.060376
198.
Hambrecht R, Gielen S, Linke A, Fiehn E, Yu J, Walther C, Schoene N, Schuler G. Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: a randomized trial. J Am Med Assoc2000;283:3095–3101.
Not in our library10.1001/jama.283.23.3095
199.
Hambrecht R, Fiehn E, Yu J, Niebauer J, Weigl C, Hilbrich L, Adams V, Riede U, Schuler G. Effects of endurance training on mitochondrial ultrastructure and fiber type distribution in skeletal muscle of patients with stable chronic heart failure. J Am Coll Cardiol1997;29:1067–1073.
Not in our library10.1016/s0735-1097(97)00015-6
200.
Esposito F, Reese V, Shabetai R, Wagner PD, Richardson RS. Isolated quadriceps training increases maximal exercise capacity in chronic heart failure: the role of skeletal muscle convective and diffusive oxygen transport. J Am Coll Cardiol2011;58:1353–1362.
Not in our library10.1016/j.jacc.2011.06.025
201.
Pedersen BK. Anti-inflammatory effects of exercise: role in diabetes and cardiovascular disease. Eur J Clin Invest2017;47:600–611.
Not in our library10.1111/eci.12781
202.
Long L, Mordi IR, Bridges C, Sagar VA, Davies EJ, Coats AJ, Dalal H, Rees K, Singh SJ, Taylor RS. Exercise-based cardiac rehabilitation for adults with heart failure. Cochrane Database Syst Rev2019;2019:CD003331.
Not in our library10.1002/14651858.cd003331.pub5
203.
Pugliese NR, Mazzola M, Madonna R, Gargani L, De Biase N, Dini FL, Taddei S, De Caterina R, Masi S. Exercise-induced pulmonary hypertension in HFpEF and HFrEF: different pathophysiologic mechanism behind similar functional impairment. Vascul Pharmacol2022;144:106978.
Not in our library10.1016/j.vph.2022.106978
204.
Kim SY, Morales CR, Gillette TG, Hill JA. Epigenetic regulation in heart failure. Curr Opin Cardiol2016;31:255–265.
Not in our library10.1097/hco.0000000000000276
205.
Felisbino MB, McKinsey TA. Epigenetics in cardiac fibrosis: emphasis on inflammation and fibroblast activation. JACC: Basic Transl Sci2018;3:704–715.
Not in our library10.1016/j.jacbts.2018.05.003
206.
Ray KK, Nicholls SJ, Ginsberg HD, Johansson JO, Kalantar-Zadeh K, Kulikowski E, Toth PP, Wong N, Cummings JL, Sweeney M, Schwartz GG. Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: rationale, design, and baseline characteristics of the BETonMACE trial. Am Heart J2019;217:72–83.
Not in our library10.1016/j.ahj.2019.08.001
207.
Bagga S, Bracht J, Hunter S, Massirer K, Holtz J, Eachus R, Pasquinelli AE. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell2005;122:553–563.
Not in our library10.1016/j.cell.2005.07.031
208.
Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell2005;120:15–20.
Not in our library10.1016/j.cell.2004.12.035
209.
Endo K, Naito Y, Ji X, Nakanishi M, Noguchi T, Goto Y, Nonogi H, Ma X, Weng H, Hirokawa G, Asada T, Kakinoki S, Yamaoka T, Fukushima Y, Iwai N. MicroRNA 210 as a biomarker for congestive heart failure. Biol Pharm Bull2013;36:48–54.
Not in our library10.1248/bpb.b12-00578
210.
Sygitowicz G, Tomaniak M, Blaszczyk O, Koltowski L, Filipiak KJ, Sitkiewicz D. Circulating microribonucleic acids miR-1, miR-21 and miR-208a in patients with symptomatic heart failure: preliminary results. Arch Cardiovasc Dis2015;108:634–642.
Not in our library10.1016/j.acvd.2015.07.003
211.
Dong S, Ma W, Hao B, Hu F, Yan L, Yan X, Wang Y, Chen Z, Wang Z. microRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating bcl-2. Int J Clin Exp Pathol2014;7:565–574.
Not in our library
212.
Gan LM, Lagerström-Fermér M, Ericsson H, Nelander K, Lindstedt EL, Michaëlsson E, Kjaer M, Heijer M, Whatling C, Fuhr R. Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo-controlled, phase I study in healthy volunteers. Br J Clin Pharmacol2019;85:762–770.
Not in our library10.1111/bcp.13855
213.
Voors AA, Kremer D, Geven C, ter Maaten JM, Struck J, Bergmann A, Pickkers P, Metra M, Mebazaa A, Düngen HD, Butler J. Adrenomedullin in heart failure: pathophysiology and therapeutic application. Eur J Heart Fail2019;21:163–171.
Not in our library10.1002/ejhf.1366
214.
Launbo N, Zobel EH, von Scholten BJ, Færch K, Jørgensen PG, Christensen RH. Targeting epicardial adipose tissue with exercise, diet, bariatric surgery or pharmaceutical interventions: a systematic review and meta-analysis. Obes Rev2021;22. Epub ahead of print 1 January 2021.
Not in our library10.1111/obr.13136

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.